Shared on 24 Jul 26

Fair value Increased 28%

PSNL: Pending Tempus Acquisition And MRD Milestones Will Support Future Upside

Tempus AI agrees to buy Personalis in an all-stock deal, and that offer is now shaping what many investors think the business is worth while the deal works its way toward approval. Alongside the takeover, Personalis hits new testing and coverage milestones for its NeXT Personal test, but the long wait to close and approval risks could still matter.

10 views

Shared on 04 Jun 26

PSNL: Ultrasensitive MRD Evidence And Expanded Coverage Will Support Balanced Future Outlook

Personalis shares get a more cautious set of analyst targets, even as new conference data suggests its blood test can spot cancer returning earlier than scans and across multiple tumor types. Medicare coverage also expands for monitoring treatment response, while the company lines up extra funding options that could shape what comes next.

8 views

Shared on 21 May 26

Fair value Decreased 3.80%

PSNL: Expanded Coverage And MRD Evidence Will Underpin Future Upside Potential

Medicare expands coverage for Personalis’ NeXT Personal test into a new use case, and fresh study results add to the real-world evidence that doctors can use it across more cancers and stages. At the same time, the company lines up a new way to raise money and analysts grow more cautious about rising spending and losses as it tries to scale.

4 views

Shared on 01 May 26

Fair value Increased 2.60%

PSNL: Medicare Coverage And MRD Data Will Support Future Upside Potential

Analysts have trimmed their price target on Personalis to $10 from $11, citing updated views on longer term operating expenses and expected net losses. These updates also feed into a slightly higher discount rate and future P/E assumptions in current models.

6 views

Shared on 21 Jan 26

PSNL: Medicare Coverage Will Shape Future Upside Despite Biopharma Headwinds

Narrative update on Personalis Analysts have lifted their blended price expectations for Personalis toward the US$9 to US$11 range, citing recent Medicare coverage for the NeXT Personal test and Q3 revenue that came in above guidance as key supports for the higher targets. Analyst Commentary Recent Street research on Personalis has focused on two main developments: Medicare coverage for the NeXT Personal test in breast cancer surveillance, and Q3 revenue that came in ahead of the guided range, internal estimates, and consensus.

35 views

Shared on 09 Dec 25

Fair value Increased 2.67%

PSNL: Medicare Reimbursement Will Drive Future Momentum Despite Biopharma Guidance Headwinds

Analysts have modestly raised their price target on Personalis, citing stronger-than-expected Q3 revenue and expanding reimbursement visibility. Their estimate of fair value has edged up from roughly $10.71 to $11.00 per share.

10 views

Shared on 24 Nov 25

Fair value Increased 26%

PSNL: Medicare Coverage Will Support Momentum Despite Guidance Headwinds

Narrative Update on Personalis Analysts have raised their price target for Personalis from approximately $8.50 to $10.71 per share. They cite recent Medicare coverage for the NeXT Personal test and stronger-than-expected quarterly revenue as supporting factors for the upward revision.

9 views

Shared on 08 Nov 25

Fair value Increased 5.43%

PSNL: Reimbursement Progress Will Drive Momentum Despite Guidance Reduction

Analysts have raised their fair value estimate for Personalis from $8.06 to $8.50 per share. They cite stronger revenue growth prospects and continued progress on reimbursement as key factors behind the upgrade.

7 views

Shared on 25 Oct 25

Fair value Increased 14%

Analysts have revised Personalis's price target downward from $8.00 to $6.00. They cite weaker than expected pharma order timing and softer profit projections, despite continued progress in clinical testing and Medicare coverage goals.

16 views

Shared on 01 May 25

Fair value Decreased 4.69%

3 views

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

0 views

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

3 views

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

2 views

Shared on 02 Apr 25

Fair value Increased 5.86%

AnalystConsensusTarget has increased future PE multiple from 45.9x to 51.0x and decreased shares outstanding growth rate from 0.3% to 0.1%.

2 views

Clinical Testing Progress And Medicare Coverage Will Influence Share Momentum Ahead

PSNL: Pending Tempus Acquisition And MRD Milestones Will Support Future Upside

PSNL: Ultrasensitive MRD Evidence And Expanded Coverage Will Support Balanced Future Outlook

PSNL: Expanded Coverage And MRD Evidence Will Underpin Future Upside Potential

PSNL: Medicare Coverage And MRD Data Will Support Future Upside Potential

PSNL: Medicare Coverage Will Shape Future Upside Despite Biopharma Headwinds

PSNL: Medicare Reimbursement Will Drive Future Momentum Despite Biopharma Guidance Headwinds

PSNL: Medicare Coverage Will Support Momentum Despite Guidance Headwinds

PSNL: Reimbursement Progress Will Drive Momentum Despite Guidance Reduction

Shared on 25 Oct 25

Shared on 01 May 25

Shared on 24 Apr 25

Shared on 17 Apr 25

Shared on 09 Apr 25

Shared on 02 Apr 25

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on Personalis

Company analysis

CEO & management